Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Chicago Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1113
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Chicago Medicine, Chicago, IL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Chicago Medicine, Chicago, IL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 661–672 of 1,113 matching trials with a site at University of Chicago Medicine, Chicago, IL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

NCT03488693
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation, No Radiation
Radiation · Other
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
35 Years and older · Female only
Enrollment
2,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
451
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 349 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 31, 2026, 11:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

NCT03924895
Site status not listed — check the official record
View directory record Official record
Conditions
Urinary Bladder Cancer, Muscle-invasive
Interventions
Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin
Drug · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
39
States / cities
Mobile, Alabama • Little Rock, Arkansas • Fullerton, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 11:15 AM EDT
Active, not recruiting Not applicable Interventional Results available

Community Mobilization for Improved Clean Cookstove Uptake, Household Air Pollution Reduction, and Hypertension Prevention

NCT05048147
Site status not listed — check the official record
View directory record Official record
Conditions
Hypertension
Interventions
Community Mobilization
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
1,280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 11:15 AM EDT
Recruiting Phase 1 Interventional

A Study of PYX-201 in Advanced Solid Tumors

NCT05720117
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumor, Advanced Solid Tumor
Interventions
PYX-201
Drug
Lead sponsor
Pyxis Oncology, Inc
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
17
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 11:15 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery

NCT06664775
Status at this site: Recruiting
View directory record Official record
Conditions
Hemorrhage
Interventions
TachoSil, Surgicel Original
Biological
Lead sponsor
Corza Medical GmbH
Industry
Eligibility
1 Month and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Torrance, California • Lakewood, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 11:15 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

NCT03012100
Site status not listed — check the official record
View directory record Official record
Conditions
Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unilateral Breast Carcinoma
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Placebo Administration, Sargramostim
Drug · Other · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • Duarte, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 11:15 AM EDT
Recruiting Not applicable Interventional

Impact of Barostimulation on Hemodynamics in Adults With Heart Failure

NCT07335510
Status at this site: Not yet recruiting
View directory record Official record
Conditions
HFrEF - Heart Failure With Reduced Ejection Fraction
Interventions
Baroreflex Activation Therapy
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 31, 2026, 11:15 AM EDT
Recruiting Phase 3 Interventional

Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome

NCT06066502
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Respiratory Failure
Interventions
Precision ventilation, Guided usual care ventilation
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
33
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 31, 2026, 11:15 AM EDT
Recruiting Phase 1 Interventional

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

NCT03571321
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
Interventions
Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 39 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 31, 2026, 11:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Total Intravenous Anesthesia vs Spinal Anesthesia in Patients Undergoing Unilateral Primary Total Knee Arthroplasty

NCT07672301
Status at this site: Recruiting
View directory record Official record
Conditions
Total Knee Arthroplasty (TKA)
Interventions
Total IntraVenous Anesthesia (TIVA), Spinal-Block, Electroencephalogram (EEG)
Combination Product · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 31, 2026, 11:15 AM EDT
Active, not recruiting Phase 1 Interventional

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

NCT01829568
Site status not listed — check the official record
View directory record Official record
Conditions
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma
Interventions
Ibrutinib, Lenalidomide, Rituximab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 31, 2026, 11:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Troriluzole in Adult Participants With Spinocerebellar Ataxia

NCT03701399
Site status not listed — check the official record
View directory record Official record
Conditions
Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10
Interventions
troriluzole, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 31, 2026, 11:15 AM EDT

About this University of Chicago Medicine institution page

What this page lists
ClinicalTrials.gov records that list University of Chicago Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.